{"Drugs":{"Drug":{"Id":10309,"DrugType":{"Type":"Small molecule therapeutic"},"DrugTargetMaturity":{"TargetIndication":[{"IndicationId":3246,"IndicationName":"Hormone refractory prostate cancer","MinPatentApplicationDate":"2013-03-25T00:00:00Z","TargetId":"PTGT-00578","TargetName":"Cytochrome P450 17"},{"IndicationId":49,"IndicationName":"Breast tumor","MinPatentApplicationDate":"2008-06-06T00:00:00Z","TargetId":"PTGT-00578","TargetName":"Cytochrome P450 17"},{"IndicationId":3247,"IndicationName":"Hormone dependent prostate cancer","MinPatentApplicationDate":"2015-12-25T00:00:00Z","TargetId":"PTGT-00578","TargetName":"Cytochrome P450 17"},{"IndicationId":276,"IndicationName":"Prostate tumor","MinPatentApplicationDate":"2006-03-02T00:00:00Z","TargetId":"PTGT-00578","TargetName":"Cytochrome P450 17"}]},"DevelopmentStatusCurrent":{"Row":[{"Company":{"@id":"17403","$":"Janssen Inc"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"3247","$":"Hormone dependent prostate cancer"},"StatusDate":"2018-02-15T00:00:00Z","SourceLink":{"@type":"PR","@id":"2005447"}},{"Company":{"@id":"17403","$":"Janssen Inc"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2011-07-28T00:00:00Z","SourceLink":{"@type":"SERIAL","@id":"1430249"}},{"Company":{"@id":"17408","$":"Janssen Pharmaceutical KK"},"Country":{"@id":"TW","$":"Taiwan"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"3247","$":"Hormone dependent prostate cancer"},"StatusDate":"2018-02-08T00:00:00Z","SourceLink":{"@type":"PR","@id":"2003610"}},{"Company":{"@id":"17408","$":"Janssen Pharmaceutical KK"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2014-09-02T00:00:00Z","SourceLink":{"@type":"PR","@id":"1589696"}},{"Company":{"@id":"17408","$":"Janssen Pharmaceutical KK"},"Country":{"@id":"TW","$":"Taiwan"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2013-12-31T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"1547561"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"EU","$":"EU"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"3247","$":"Hormone dependent prostate cancer"},"StatusDate":"2017-11-20T00:00:00Z","SourceLink":{"@type":"PR","@id":"1984051"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"DK","$":"Denmark"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2011-10-03T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"1420325"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"EU","$":"EU"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2011-09-22T00:00:00Z","SourceLink":{"@type":"PR","@id":"1224550"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"DE","$":"Germany"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2011-10-31T00:00:00Z","SourceLink":{"@type":"SERIAL","@id":"1337270"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"NO","$":"Norway"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2011-11-15T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"1459391"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"KR","$":"South Korea"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2012-09-30T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"1782302"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"CH","$":"Switzerland"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2012-04-01T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"1616463"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"GB","$":"UK"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2011-09-22T00:00:00Z","SourceLink":{"@type":"PR","@id":"1224550"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"BR","$":"Brazil"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"3247","$":"Hormone dependent prostate cancer"},"StatusDate":"2018-02-08T00:00:00Z","SourceLink":{"@type":"PR","@id":"2003610"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"CN","$":"China"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"3247","$":"Hormone dependent prostate cancer"},"StatusDate":"2018-12-04T00:00:00Z","SourceLink":{"@type":"PR","@id":"2101401"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"3247","$":"Hormone dependent prostate cancer"},"StatusDate":"2018-02-16T00:00:00Z","SourceLink":{"@type":"PR","@id":"2005956"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"KE","$":"Kenya"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"3247","$":"Hormone dependent prostate cancer"},"StatusDate":"2019-02-08T00:00:00Z","SourceLink":{"@type":"PR","@id":"2118116"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"3247","$":"Hormone dependent prostate cancer"},"StatusDate":"2018-02-08T00:00:00Z","SourceLink":{"@type":"PR","@id":"2003610"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"BR","$":"Brazil"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2013-08-02T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"1647989"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"CN","$":"China"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2016-12-31T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"1903902"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"KE","$":"Kenya"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2019-02-08T00:00:00Z","SourceLink":{"@type":"PR","@id":"2118116"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"PT","$":"Portugal"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2011-10-20T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"1365520"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"TT","$":"Trinidad and Tobago"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2014-04-11T00:00:00Z","SourceLink":{"@type":"PR","@id":"1546385"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"L","@sortorder":"15","$":"Launched"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2011-05-31T00:00:00Z","SourceLink":{"@type":"SERIAL","@id":"1272755"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"AU","$":"Australia"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2012-02-27T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"1753868"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"CN","$":"China"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"49","$":"Breast tumor"},"StatusDate":"2018-03-21T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"2009262"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"MX","$":"Mexico"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"3247","$":"Hormone dependent prostate cancer"},"StatusDate":"2017-09-14T00:00:00Z","SourceLink":{"@type":"PR","@id":"1962370"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"PH","$":"Philippines"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"3247","$":"Hormone dependent prostate cancer"},"StatusDate":"2017-09-14T00:00:00Z","SourceLink":{"@type":"PR","@id":"1962370"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"SG","$":"Singapore"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"3247","$":"Hormone dependent prostate cancer"},"StatusDate":"2017-09-14T00:00:00Z","SourceLink":{"@type":"PR","@id":"1962370"}},{"Company":{"@id":"1067538","$":"Janssen Research & Development LLC"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"3657","$":"Metastatic breast cancer"},"StatusDate":"2011-08-31T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1307495"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"X5","$":"Europe"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"3657","$":"Metastatic breast cancer"},"StatusDate":"2009-07-10T00:00:00Z","SourceLink":{"@type":"PR","@id":"1024776"}},{"Company":{"@id":"14881","$":"Boehringer Ingelheim International GmbH"},"Country":{"@id":"GB","$":"UK"},"DevelopmentStatus":{"@id":"NDR","@sortorder":"3","$":"No Development Reported"},"Indication":{"@id":"276","$":"Prostate tumor"},"StatusDate":"1999-01-22T00:00:00Z"},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"NDR","@sortorder":"3","$":"No Development Reported"},"Indication":{"@id":"1654","$":"Congenital adrenal hyperplasia"},"StatusDate":"2014-08-31T00:00:00Z"},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"RU","$":"Russian Federation"},"DevelopmentStatus":{"@id":"NDR","@sortorder":"3","$":"No Development Reported"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2012-11-26T00:00:00Z"},{"Company":{"@id":"15266","$":"BTG plc"},"Country":{"@id":"GB","$":"UK"},"DevelopmentStatus":{"@id":"OL","@sortorder":"1","$":"Outlicensed"},"Indication":{"@id":"276","$":"Prostate tumor"},"StatusDate":"2004-04-20T00:00:00Z","SourceLink":{"@type":"PR","@id":"533875"}},{"Company":{"@id":"24077","$":"Cancer Research Campaign Technology Ltd"},"Country":{"@id":"GB","$":"UK"},"DevelopmentStatus":{"@id":"OL","@sortorder":"1","$":"Outlicensed"},"Indication":{"@id":"276","$":"Prostate tumor"},"StatusDate":"1994-12-31T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"222422"}}]},"DevelopmentStatusHistoric":{"Row":[{"Company":{"@id":"26997","$":"Janssen Biotech Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2011-04-28T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"1211974"}},{"Company":{"@id":"17403","$":"Janssen Inc"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2011-07-28T00:00:00Z","SourceLink":{"@type":"PR","@id":"1211053"}},{"Company":{"@id":"17408","$":"Janssen Pharmaceutical KK"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2014-07-04T00:00:00Z","SourceLink":{"@type":"SERIAL","@id":"1577972"}},{"Company":{"@id":"17408","$":"Janssen Pharmaceutical KK"},"Country":{"@id":"TW","$":"Taiwan"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2013-08-30T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"1547561"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"EU","$":"EU"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"3247","$":"Hormone dependent prostate cancer"},"StatusDate":"2017-11-20T00:00:00Z","SourceLink":{"@type":"PR","@id":"1984051"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"CN","$":"China"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2015-04-03T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"1650263"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"EU","$":"EU"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2011-09-07T00:00:00Z","SourceLink":{"@type":"PR","@id":"1220746"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"KR","$":"South Korea"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2012-07-10T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"1747964"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"CH","$":"Switzerland"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2012-04-01T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"1616463"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"BR","$":"Brazil"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"3247","$":"Hormone dependent prostate cancer"},"StatusDate":"2018-02-08T00:00:00Z","SourceLink":{"@type":"PR","@id":"2003610"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"3247","$":"Hormone dependent prostate cancer"},"StatusDate":"2018-02-15T00:00:00Z","SourceLink":{"@type":"PR","@id":"2005447"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"CN","$":"China"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"3247","$":"Hormone dependent prostate cancer"},"StatusDate":"2018-12-04T00:00:00Z","SourceLink":{"@type":"PR","@id":"2101401"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"3247","$":"Hormone dependent prostate cancer"},"StatusDate":"2018-02-16T00:00:00Z","SourceLink":{"@type":"PR","@id":"2005956"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"TW","$":"Taiwan"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"3247","$":"Hormone dependent prostate cancer"},"StatusDate":"2018-02-08T00:00:00Z","SourceLink":{"@type":"PR","@id":"2003610"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"3247","$":"Hormone dependent prostate cancer"},"StatusDate":"2018-02-08T00:00:00Z","SourceLink":{"@type":"PR","@id":"2003610"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"BR","$":"Brazil"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2013-08-02T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"1647989"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"TT","$":"Trinidad and Tobago"},"DevelopmentStatus":{"@id":"R","@sortorder":"14","$":"Registered"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2014-04-11T00:00:00Z","SourceLink":{"@type":"PR","@id":"1546385"}},{"Company":{"@id":"26997","$":"Janssen Biotech Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2010-12-20T00:00:00Z","SourceLink":{"@type":"PR","@id":"1157116"}},{"Company":{"@id":"17403","$":"Janssen Inc"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2010-12-23T00:00:00Z","SourceLink":{"@type":"PR","@id":"1157703"}},{"Company":{"@id":"17408","$":"Janssen Pharmaceutical KK"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2013-07-26T00:00:00Z","SourceLink":{"@type":"PR","@id":"1456948"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"CN","$":"China"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2013-05-23T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"1440862"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"EU","$":"EU"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2010-12-20T00:00:00Z","SourceLink":{"@type":"PR","@id":"1157116"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"BR","$":"Brazil"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"3247","$":"Hormone dependent prostate cancer"},"StatusDate":"2017-09-14T00:00:00Z","SourceLink":{"@type":"PR","@id":"1962370"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"CA","$":"Canada"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"3247","$":"Hormone dependent prostate cancer"},"StatusDate":"2017-09-14T00:00:00Z","SourceLink":{"@type":"PR","@id":"1962370"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"EU","$":"EU"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"3247","$":"Hormone dependent prostate cancer"},"StatusDate":"2017-04-18T00:00:00Z","SourceLink":{"@type":"PR","@id":"1918634"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"TW","$":"Taiwan"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"3247","$":"Hormone dependent prostate cancer"},"StatusDate":"2017-09-14T00:00:00Z","SourceLink":{"@type":"PR","@id":"1962370"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"3247","$":"Hormone dependent prostate cancer"},"StatusDate":"2017-09-14T00:00:00Z","SourceLink":{"@type":"PR","@id":"1962370"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"AU","$":"Australia"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2011-05-26T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"1197105"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"RU","$":"Russian Federation"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2011-05-26T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"1197420"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"CH","$":"Switzerland"},"DevelopmentStatus":{"@id":"PR","@sortorder":"13","$":"Pre-registration"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2011-05-26T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"1197105"}},{"Company":{"@id":"1007756","$":"Cougar Biotechnology Inc"},"Country":{"@id":"AU","$":"Australia"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2008-04-23T00:00:00Z","SourceLink":{"@type":"PR","@id":"900667"}},{"Company":{"@id":"1007756","$":"Cougar Biotechnology Inc"},"Country":{"@id":"X5","$":"Europe"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2008-04-23T00:00:00Z","SourceLink":{"@type":"PR","@id":"900667"}},{"Company":{"@id":"1007756","$":"Cougar Biotechnology Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2008-04-23T00:00:00Z","SourceLink":{"@type":"PR","@id":"900667"}},{"Company":{"@id":"17408","$":"Janssen Pharmaceutical KK"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2013-02-25T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"1386034"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"CN","$":"China"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2012-03-15T00:00:00Z"},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"XH","$":"Far East"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2012-05-02T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1385475"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"BR","$":"Brazil"},"DevelopmentStatus":{"@id":"C3","@sortorder":"12","$":"Phase 3 Clinical"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2014-04-02T00:00:00Z","SourceLink":{"@type":"PR","@id":"1541856"}},{"Company":{"@id":"1007756","$":"Cougar Biotechnology Inc"},"Country":{"@id":"GB","$":"UK"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2005-12-14T00:00:00Z","SourceLink":{"@type":"PR","@id":"640725"}},{"Company":{"@id":"1007756","$":"Cougar Biotechnology Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2007-02-23T00:00:00Z","SourceLink":{"@type":"PR","@id":"768379"}},{"Company":{"@id":"15266","$":"BTG plc"},"Country":{"@id":"GB","$":"UK"},"DevelopmentStatus":{"@id":"C1","@sortorder":"10","$":"Phase 1 Clinical"},"Indication":{"@id":"276","$":"Prostate tumor"},"StatusDate":"2003-10-12T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"507200"}},{"Company":{"@id":"1007756","$":"Cougar Biotechnology Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"C1","@sortorder":"10","$":"Phase 1 Clinical"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2006-07-11T00:00:00Z","SourceLink":{"@type":"PR","@id":"677968"}},{"Company":{"@id":"1007756","$":"Cougar Biotechnology Inc"},"Country":{"@id":"GB","$":"UK"},"DevelopmentStatus":{"@id":"C1","@sortorder":"10","$":"Phase 1 Clinical"},"Indication":{"@id":"276","$":"Prostate tumor"},"StatusDate":"2004-04-20T00:00:00Z","SourceLink":{"@type":"PR","@id":"533875"}},{"Company":{"@id":"17408","$":"Janssen Pharmaceutical KK"},"Country":{"@id":"JP","$":"Japan"},"DevelopmentStatus":{"@id":"C1","@sortorder":"10","$":"Phase 1 Clinical"},"Indication":{"@id":"3246","$":"Hormone refractory prostate cancer"},"StatusDate":"2010-06-30T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1151800"}},{"Company":{"@id":"17332","$":"Johnson & Johnson"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"C1","@sortorder":"10","$":"Phase 1 Clinical"},"Indication":{"@id":"1654","$":"Congenital adrenal hyperplasia"},"StatusDate":"2011-12-22T00:00:00Z","SourceLink":{"@type":"TRIALREG","@id":"1251658"}},{"Company":{"@id":"15266","$":"BTG plc"},"Country":{"@id":"GB","$":"UK"},"DevelopmentStatus":{"@id":"DR","@sortorder":"7","$":"Discovery"},"Indication":{"@id":"276","$":"Prostate tumor"},"StatusDate":"1994-12-31T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"222422"}},{"Company":{"@id":"14881","$":"Boehringer Ingelheim International GmbH"},"Country":{"@id":"GB","$":"UK"},"DevelopmentStatus":{"@id":"DR","@sortorder":"7","$":"Discovery"},"Indication":{"@id":"276","$":"Prostate tumor"},"StatusDate":"1995-06-05T00:00:00Z","SourceLink":{"@type":"SERIAL","@id":"178328"}},{"Company":{"@id":"24077","$":"Cancer Research Campaign Technology Ltd"},"Country":{"@id":"GB","$":"UK"},"DevelopmentStatus":{"@id":"DR","@sortorder":"7","$":"Discovery"},"Indication":{"@id":"276","$":"Prostate tumor"},"StatusDate":"1994-12-01T00:00:00Z","SourceLink":{"@type":"SERIAL","@id":"178401"}},{"Company":{"@id":"1007756","$":"Cougar Biotechnology Inc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"DR","@sortorder":"7","$":"Discovery"},"Indication":{"@id":"276","$":"Prostate tumor"},"StatusDate":"2006-02-02T00:00:00Z","SourceLink":{"@type":"PR","@id":"648454"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"CN","$":"China"},"DevelopmentStatus":{"@id":"DR","@sortorder":"7","$":"Discovery"},"Indication":{"@id":"49","$":"Breast tumor"},"StatusDate":"2012-07-09T00:00:00Z","SourceLink":{"@type":"PR","@id":"1384043"}},{"Company":{"@id":"17392","$":"Janssen-Cilag Ltd"},"Country":{"@id":"CN","$":"China"},"DevelopmentStatus":{"@id":"DR","@sortorder":"7","$":"Discovery"},"Indication":{"@id":"276","$":"Prostate tumor"},"StatusDate":"2010-11-18T00:00:00Z","SourceLink":{"@type":"OTHER","@id":"1385481"}}]}}}}